These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Safe and effective treatment of refractory facial lesions in atopic dermatitis using topical tacrolimus following corticosteroid discontinuation. Kawakami T; Soma Y; Morita E; Koro O; Yamamoto S; Nakamura K; Tamaki K; Yajima K; Imaizumi A; Matsunaga R; Murakami N; Kashima M; Mizoguchi M Dermatology; 2001; 203(1):32-7. PubMed ID: 11549797 [TBL] [Abstract][Full Text] [Related]
11. Administrative claims analysis of utilization and costs of care in health plan members with atopic dermatitis who had prior use of a topical corticosteroid and who initiate therapy with pimecrolimus or tacrolimus. Delea TE; Gokhale M; Makin C; Hussein MA; Vanderpoel J; Sandman T; Chang J; Sung J; Pinkston P; Gause D; Jackson M J Manag Care Pharm; 2007 May; 13(4):349-59. PubMed ID: 17506601 [TBL] [Abstract][Full Text] [Related]
12. Bilateral comparison study of pimecrolimus cream 1% and a ceramide-hyaluronic acid emollient foam in the treatment of patients with atopic dermatitis. Frankel A; Sohn A; Patel RV; Lebwohl M J Drugs Dermatol; 2011 Jun; 10(6):666-72. PubMed ID: 21637908 [TBL] [Abstract][Full Text] [Related]
13. A multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis. Reitamo S; Ortonne JP; Sand C; Cambazard F; Bieber T; Fölster-Holst R; Vena G; Bos JD; Fabbri P; Groenhoej Larsen C; Br J Dermatol; 2005 Jun; 152(6):1282-9. PubMed ID: 15948994 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials. Ashcroft DM; Dimmock P; Garside R; Stein K; Williams HC BMJ; 2005 Mar; 330(7490):516. PubMed ID: 15731121 [TBL] [Abstract][Full Text] [Related]
15. Tacrolimus ointment. A review of its therapeutic potential as a topical therapy in atopic dermatitis. Cheer SM; Plosker GL Am J Clin Dermatol; 2001; 2(6):389-406. PubMed ID: 11770393 [TBL] [Abstract][Full Text] [Related]
16. Formulary review of therapeutic alternatives for atopic dermatitis: focus on pimecrolimus. Weinberg JM J Manag Care Pharm; 2005; 11(1):56-64. PubMed ID: 15667233 [TBL] [Abstract][Full Text] [Related]
17. Effects of topical corticosteroid and tacrolimus on ceramides and irritancy to sodium lauryl sulphate in healthy skin. Jungersted JM; Høgh JK; Hellegren LI; Jemec GB; Agner T Acta Derm Venereol; 2011 May; 91(3):290-4. PubMed ID: 21365172 [TBL] [Abstract][Full Text] [Related]
18. A single-center open-label long-term comparison of tacrolimus ointment and topical corticosteroids for treatment of atopic dermatitis. Neumann E; Amtage D; Bruckner-Tuderman L; Mockenhaupt M J Dtsch Dermatol Ges; 2008 Jul; 6(7):548-53. PubMed ID: 18248495 [TBL] [Abstract][Full Text] [Related]
19. Testing an Ectoin Containing Emollient for Atopic Dermatitis. Hon KL; Kung JS; Ng WGG; Leung TF Curr Pediatr Rev; 2019; 15(3):191-195. PubMed ID: 30987568 [TBL] [Abstract][Full Text] [Related]
20. A randomized, open-label study to evaluate an intermittent dosing regimen of fluticasone propionate 0.05% cream in combination with regular emollient skin care in reducing the risk of relapse in pediatric patients with stabilized atopic dermatitis. Liu L; Ong G J Dermatolog Treat; 2018 Aug; 29(5):501-509. PubMed ID: 29164960 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]